What Does ImCheck Therapeutics Do?

Total employees56
HeadquartersMarseille
Founded2015

ImCheck Therapeutics is a biotechnology company at the forefront of immuno-oncology, designing and developing a new generation of immunotherapeutic antibodies. Their pioneering approach targets butyrophilins, a novel super-family of immunomodulators, to unleash the therapeutic potential of gamma-delta (γδ) T cells and other immune cells. ImCheck's pipeline includes first-in-class antibodies and fusion proteins aimed at treating various forms of cancer and autoimmune diseases, with lead candidates progressing through clinical trials.

Where Is ImCheck Therapeutics's Headquarters?

HQ Function

Primary hub for research and development (R&D), corporate operations, and strategic management, focused on advancing their pipeline of immuno-oncology therapies targeting butyrophilins and γδ T cells.

Notable Features:

Located within Parc Scientifique de Luminy, a major French science and technology park in Marseille, offering modern laboratory and office facilities. Proximity to leading academic research institutions and a vibrant biotech ecosystem.

Work Culture:

A dynamic, science-driven, and collaborative environment focused on innovation in immunotherapy. Emphasizes teamwork, scientific rigor, and translating cutting-edge research into clinical solutions for patients.

HQ Significance:

Strategic location in Marseille, a key French biotech hub, provides access to specialized talent, research collaborations, and a supportive infrastructure for life sciences innovation. Serves as the central node for global operations.

Values Reflected in HQ: The headquarters reflects values of innovation, scientific excellence, collaboration, and a patient-centric approach to developing novel cancer and autoimmune disease therapies.

Location:

ImCheck Therapeutics supports its global clinical trials, research collaborations, and business development activities from its headquarters in France and through its clinical operations presence in the United States (Cambridge, MA). This dual presence allows them to effectively manage international studies and engage with key stakeholders in both Europe and North America.

Street Address:

Parc Scientifique de Luminy, Biotech III – Zone Entreprises, 163 Avenue de Luminy

City:

Marseille

State/Province:

Provence-Alpes-Côte d'Azur

Country:

France

Where Else Does ImCheck Therapeutics Operate Around the World?

Cambridge, Massachusetts/USA

Address: Clinical operations office in Cambridge, MA (Specific address not publicly listed, likely flexible or shared office space).

To facilitate the advancement of ImCheck's clinical pipeline in North America, engage with the vibrant US biotech ecosystem, and support interactions with regulatory bodies like the FDA.

Buying Intent Signals for ImCheck Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading ImCheck Therapeutics? Meet the Executive Team

As of April 2025, ImCheck Therapeutics' leadership includes:

Pierre d’Epenoux - Chief Executive Officer
Déborah Cicurel - Chief Financial Officer
Paul Frohna, MD, PhD, PharmD - Chief Medical Officer
René Hoet, PhD - Chief Scientific Officer
Patrick Welsch - Chief Operating Officer

Who's Investing in ImCheck Therapeutics?

ImCheck Therapeutics has been backed by several prominent investors over the years, including:

Pfizer Ventures
Bpifrance (including InnoBio 2 and Large Venture funds)
Eurazeo (formerly Idinvest Partners)
Kurma Partners
Gimv
Wellington Partners
EQT Life Sciences (formerly LSP)
Invus
Agent Capital
Andera Partners
Eurekare
The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP)

What Leadership Changes Has ImCheck Therapeutics Seen Recently?

Hire0
Exits1

ImCheck Therapeutics has seen limited C-suite changes in the past 12 months, with one notable departure in a key development leadership role. The core executive team leading strategy, finance, medical, and scientific operations has remained stable.

Departures

Hans van der Vliet, Dr. Hans van der Vliet transitioned from his role as Chief Development Officer.

What Technology (Tech Stack) Is Used byImCheck Therapeutics?

Discover the tools ImCheck Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

ImCheck Therapeutics Email Formats and Examples

ImCheck Therapeutics commonly uses an email format consisting of the employee's first initial followed by their last name, then '@imcheck.com'. Variations might exist but this is a frequently observed pattern.

[first_initial][last]@imcheck.com

Format

pdepenoux@imcheck.com

Example

75%

Success rate

What's the Latest News About ImCheck Therapeutics?

Business WireMay 2, 2024

ImCheck Therapeutics Announces First Patient Dosed in EVICTION-2 Trial for Bladder Cancer

ImCheck Therapeutics has initiated dosing in its EVICTION-2 Phase 2a clinical trial, evaluating its lead candidate ICT01 in combination with pembrolizumab for treating patients with platinum-resistant/refractory urothelial carcinoma (bladder cancer)....more

ImCheck Therapeutics WebsiteApril 8, 2024

ImCheck Presents Preclinical Data on ICT04 and ICT01 Trial Design at AACR 2024

ImCheck Therapeutics presented promising preclinical data for its CD39-targeting immunocytokine ICT04 and outlined the clinical trial design for ICT01 in Acute Myeloid Leukemia (AML) at the American Association for Cancer Research (AACR) Annual Meeting 2024....more

ImCheck Therapeutics WebsiteJanuary 18, 2024

ImCheck Therapeutics Presents at January 2024 Investor Conferences

ImCheck Therapeutics announced its participation and presentations at several key investor conferences in January 2024, highlighting its pipeline progress and corporate strategy to the investment community....more

ImCheck Therapeutics WebsiteDecember 12, 2023

ImCheck Therapeutics to Present at the 65th ASH Annual Meeting and Exposition

ImCheck Therapeutics announced its upcoming presentations at the 65th American Society of Hematology (ASH) Annual Meeting, showcasing data related to its hematological malignancy programs....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including ImCheck Therapeutics, are just a search away.